BRAF and colorectal carcinoma: Here, for the primary screen we exploited previous observations that selection of CRC cells deprived of Ras pathway-activating mutations under glucose-limiting conditions yields reverting clones (Fig. 1a and b), of which a subset contain de novo activating hotspot mutations in KRAS or BRAF [6], followed by subsequent validation of candidate genes in other Ras pathway phenotypes.